Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity

NCT05812183 on ClinicalTrials.gov · last registry update 2025-02-14

Withdrawn before anyone was enrolled. Its estimated completion date, 12 February 2025, has passed with no update to the record. Primary outcome, as filed: Dyspnea. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.

Status: WITHDRAWN
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of California, Los Angeles
Sponsor type: Other
Enrollment: 0
Started: 2023-07-09
Primary completion: 2025-02-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Dyspnea

Conditions studied

Dyspnea · Quality of Life

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.